Mvasi (bevacizumab)

pCPA File Number: 21696

Negotiation Status:

Concluded with an LOI

Indication(s):

Carcinoma of the colon or rectum, metastatic, first-line treatment in combination with fluoropyrimidine based chemotherapy or patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer, in combination with carboplatin/paclitaxel chemotherapy regimen

Sponsor/Manufacturer:

Amgen Canada Inc.

CDA-AMC Project Number:

Not Applicable

pCPA Engagement Letter Issued:

2022-01-14

Negotiation Process Concluded:

2022-01-14